



September 2017 Newsletter

Volume 5 Issue 8

A Letter from the Founder, Dr. Christine Brezden- Masley

Dear CCTC Members,

Since the launch of the CCTC in 2011, the consortium has remarkably expanded to over 260 members across 31 institutions, including 12 of the major cancer centres in Ontario.

We greatly value any input, feedback, and suggestions in order to make your experience with the site as user-friendly as possible. E-mail us at cometrials@smh.ca and we will be more than happy to assist.

Sincerely,

Dr. Christine Brezden-Masley
Founder, CCTC

A Letter from the Project Manager, Nicole Veloce

Hello CCTC Members,

I would like to take this opportunity to introduce myself. My name is Nicole Veloce and I am a Research Assistant working in the Hematology Oncology Clinical Research Group at St. Michael's Hospital. I will be the Project Manager from now until December. I look forward to supporting COMET in the upcoming months.

If you have an accruing trial you would like to highlight, please email cometrials@smh.ca to nominate it to be one of our next *Trials of the Month*. As always, please contact me at cometrials@smh.ca any time with questions, comments or concerns.

Kind Regards,

Nicole Veloce

Project Manager, CCTC

ARTICLE RECOMMENDATION

Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement

Chad Tang, Steven I. Sherman, Mellanie Price, Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman Buzdar, George Wilding and J. Jack Lee

Clin Cancer Res; 23(6); 1414–21.

DOI: 10.1158/1078-0432.CCR-16-2439, Published March 2017

Purpose: Slow-accruing clinical trials delay the translation of basic biomedical research, contribute to increasing health care costs, and may prohibit trials from reaching their original goals.

Experimental Design: We analyzed a prospectively maintained institutional database that tracks all clinical studies at the MD Anderson Cancer Center (Houston, TX). Inclusion criteria were activated phase I–III trials, maximum projected accrual ≥ 10 participants, and activation prior to March 25, 2011. The primary outcome was slow accrual, defined as < 2 participants per year. Correlations of trial characteristics with slow accrual were assessed with logistic regression.

Results: A total of 4,269 clinical trials met inclusion criteria. Trials were activated between January 5, 1981, and March 25, 2011, with a total of 145,214 participants enrolled. Median total enrolment was 16 [interquartile range (IQR), 5–34], with an average enrolment rate of 8.7 participants per year (IQR, 3.3–17.7). There were 755 (18%) trials classified as slow accruing. On multivariable analysis, slow accrual exhibited robust associations with national cooperative group trials (OR = 4.16, $P < 0.0001$ vs. industry sponsored), time from trial activation to first enrolment (OR = 1.13 per month, $P < 0.0001$), and maximum targeted accrual (OR = 0.16 per log₁₀ increase, $P < 0.0001$). Recursive partitioning analysis identified trials requiring more than 70 days (2.3 months) between activation and first participant enrolment as having higher odds of slow accrual (23% vs. 5%, OR = 5.56, $P < 0.0001$).

Conclusions: We identified factors associated with slow trial accrual. Given the lack of data on clinical trials at the institutional level, these data will help build a foundation from which targeted initiatives may be developed to improve

TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Total
Imaging Study	-	-	-	-	3	2	-	-	-	-	3
Observational	1	2	-	-	1	1	-	1	-	-	6
Prevention	-	1	-	1	-	-	-	1	-	-	3
Radiation	-	3	-	3	5	-	1	1	6	-	18
Supportive Care	1	4	-	-	-	-	-	-	-	-	5
Surgical Therapy	-	1	1	-	1	1	-	-	-	-	4
Systemic Therapy	1	12	1	13	21	6	2	12	12	7	81
Therapeutic	-	1	-	-	2	1	-	3	-	-	6
TOTAL	3	24	2	17	33	11	3	18	18	7	126



September 2017 Newsletter

Volume 5, Issue 8

TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	<u>MAC.20/ BWEL</u>	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer.	<ul style="list-style-type: none"> • Adjuvant • Prevention 	Cambridge Memorial Hospital
GU	<u>FASTR 2</u>	Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer – Protocol 2.	<ul style="list-style-type: none"> • Prostate Cancer • Adjuvant • Radiation Therapy 	London Health Sciences Centre
Heme	<u>MYX1</u>	A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies	<ul style="list-style-type: none"> • Multiple Myeloma • Relapse/Refractory • Systemic Therapy 	Kingston General Hospital
GYN	<u>FORWARD 1</u>	FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer	<ul style="list-style-type: none"> • Ovarian • Metastatic • Systemic Therapy 	London Health Sciences Centre
Lung	<u>BR.34</u>	A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With High-Risk Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	<ul style="list-style-type: none"> • Non-Small Cell • Metastatic • Systemic Therapy 	Cambridge Memorial Hospital
GI	<u>Q-CROC-01</u>	Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer	<ul style="list-style-type: none"> • Colorectal • Metastatic • Systemic Therapy 	Mount Sinai Hospital Odette Cancer Centre



[Click here to NOMINATE your trial for Trials of the Month!](#)



MEMBERSHIP UPDATES

276 members

31 institutions

126 accruing trials



ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8

cometrials@smh.ca
(416) 809-3915

[@COMET_Trials](https://www.cometrials.com)

www.cometrials.com

INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	5
Grand River Hospital	Waterloo	11	1
Humber River Regional Hospital	Toronto	6	3
Kingston General Hospital	Kingston	4	26
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	23	-
London Health Sciences Centre	London	9	66
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	1
Mount Sinai Hospital	Toronto	2	4
North York General Hospital	Toronto	15	5
Odette Cancer Centre/Sunnybrook	Toronto	56	41
Ontario Institute for Cancer Research	Toronto	8	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	23	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	23	18
Scarborough General Hospital	Toronto	2	-
Southlake Regional Health Centre	Newmarket	19	12
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	16	6
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Toronto East General Hospital	Toronto	7	-
Trillium Health Partners	Mississauga	16	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	1	-
Wingham and District Hospital	Wingham	1	-